Evidence-driven updates across biotech and AI

Articles, whitepapers and podcasts from our team and advisors.

Podcasts
•External link

AI, LABI, and How we Invest: A Conversation with Neel Madhukar, PhD and Themasap Khan, PhD

Neel Madhukar, PhD, Chief Technology Officer of Luma Group’s proprietary AI model, LABI, discusses the genesis of the program and how it impacts day-to-day processes at Luma Group. Neel and Themasap discuss what we are building at Luma Group to change the game for biotech investing.

See More
Whitepapers

God Bless the Private Sector: How Private Funding is Bridging the Gap

Publicly funded basic research has long served as the foundation for breakthroughs. Yet proposed federal cuts, including reductions to the NSF and NIH, now threaten the early-stage research that the private sector traditionally does not fund. These changes have already stalled projects, eliminated jobs, and raised concerns about broader delays in scientific progress. At the same time, the United States faces intensifying competition with China, whose sustained investment in early-stage biotech has accelerated its global share of drug development. Although the US retains leadership in total R&D value, the trend signals growing vulnerability, one seemingly at odds with the administration’s broader “America First” agenda. The launch of the Genesis Mission, with its emphasis on AI-enabled science and biotechnology as a domain of national importance, hints at a potential restructuring rather than an abandonment of federal scientific priorities. In this environment, the private sector has emerged as an essential stabilizing force. As public funding recedes, venture capital and philanthropy must intervene earlier in the research lifecycle. This shift can bring rigorous private-sector diligence to basic science, likely focusing resources on fewer projects but with greater efficiency. To handle this complexity, biology-specific AI tools will shift from optional luxuries to indispensable necessities. Ultimately, this disruption offers a chance to modernize our infrastructure: building a resilient ecosystem capable of expanding, not just restoring, American scientific progress.

See More
AllPodcastsWhitepapersArticles
Whitepapers

Data-Driven Biotechnology: How Multi-Omics Analytics Are Shaping the Future of Medicine

Innovation in biotechnology is driven by uncovering novel biological insights and translating them into life-saving therapeutics, diagnostics and medical devices. Over the past two decades, breakthroughs have largely stemmed from analyzing vast biological datasets, such as those generated by human genome projects. Today, advancements in artificial intelligence (AI) and machine learning (ML) have significantly enhanced our ability to systematically analyze massive datasets, identifying complex relationships across genomic, proteomic, transcriptomic, metabolomic and other data simultaneously. The cross-section of all of these “-omics” is what we define as multi-omics, which represents a large untapped domain for future biotech innovation. The convergence of affordable, sophisticated AI/ML analytics and large-scale multi-omics data collection has marked a pivotal shift within biotechnology, from single-omics approaches to integrated multi-omics innovations.

See More
Whitepapers

Decoding Aging: Breakthroughs, Challenges and the Future of Longevity Drug Development

For centuries, humans have sought to understand—and potentially slow, halt or reverse—the aging process. Recent advances in molecular and cellular biology have begun to illuminate the core hallmarks and drivers of aging, providing a foundational framework for new therapeutic approaches. While some of these therapies have not fulfilled their initial promise, others have achieved remarkable progress, and ongoing clinical trials may pave the way for a new class of longevity drugs. Still, despite growing optimism, the journey toward regulatory approval and widespread adoption of these treatments presents a unique set of challenges that must be navigated carefully.

See More
Whitepapers

Unlocking Cures: The Path from Concept to Human Clinical Trials

Advances in drug development and discovery have revolutionized the delivery of life-saving treatments to patients. Despite the immense impact of these innovations, the journey from concept to bedside remains largely misunderstood. Through this primer series, we explore the complex processes behind drug discovery, highlighting the challenges the industry still faces and the critical need for investment of time and resources to deliver the next generation of medicines.

See More
Whitepapers

From Hippocrates to Hyperspeed: How AI Will Catalyze Advancements in Life Science

The AI revolution’s impact on society, particularly healthcare, is set to surpass the transformative effects of the Industrial and Information Revolutions. Real-world evidence of this can be seen in the application of AI-driven diagnostics and therapeutics, which have significantly enhanced the accuracy and speed of disease detection and rate of targeting and curing disease. The forthcoming role of AI in healthcare is ambitious yet achievable but requires a level of collaboration, innovation, and dedication to a brighter and healthier future.

See More
Whitepapers

Precision Therapy: Applying Proven Technologies to Inflammatory and Immunological Disease Treatment

The convergence of various factors, including advancements in OMIC data, repurposing of precision oncology technologies and high demand from patients and pharmaceutical companies, has positioned inflammation and immunology sectors for explosive growth, driving the development of safer and more effective precision therapies.

See More